Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BMS-201620: a selective beta 3 agonist.

W N Washburn1, C-Q Sun, G Bisacchi

  • 1Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543, USA. william.washburn@bms.com

Bioorganic & Medicinal Chemistry Letters
|June 5, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MiniBooNE and MicroBooNE Combined Fit to a 3+1 Sterile Neutrino Scenario.

Physical review letters·2022
Same author

Mupirocin, fusidic acid and bacitracin: activity, action and clinical uses of three topical antibiotics.

Veterinary dermatology·2021
Same author

Estimates of the effects of physical activity on osteoporosis using multivariable Mendelian randomization analysis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Detecting causal relationship between metabolic traits and osteoporosis using multivariable Mendelian randomization.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Systematic review: exosomal microRNAs associated with pancreatic cancer for early detection and prognosis.

European review for medical and pharmacological sciences·2019
Same author

Significant Excess of Electronlike Events in the MiniBooNE Short-Baseline Neutrino Experiment.

Physical review letters·2018
Same journal

Discovery of a potent sGC stimulator with once-daily dosing potential for the treatment of hypertension.

Bioorganic & medicinal chemistry letters·2026
Same journal

OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.

Bioorganic & medicinal chemistry letters·2026
Same journal

Rational design and N-terminal acylation of a lactam-cyclized 11-residue antimicrobial peptide for improved antibacterial potency.

Bioorganic & medicinal chemistry letters·2026
Same journal

Rational design, synthesis, and biological evaluation of chalcone hybrids including benzoylpiperazin (phenylacetylpiperazin)-thiophene as anti- Alzheimer's agents.

Bioorganic & medicinal chemistry letters·2026
Same journal

New aminopiperidine-azoles as antifungal agents against Candida albicans with mechanistic insights into the cAMP-PKA pathway.

Bioorganic & medicinal chemistry letters·2026
Same journal

Novel 1H-pyrrole-2,5-dione derivatives as potential anti-diabetic agents: design, synthesis, in vitro, in ovo, and molecular docking studies.

Bioorganic & medicinal chemistry letters·2026
See all related articles
This summary is machine-generated.

Researchers developed new compounds targeting the human beta3 adrenergic receptor. BMS-201620 demonstrated potent full agonist activity and a favorable safety profile, leading to its selection for clinical trials.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Drug Discovery

Background:

  • The beta3 adrenergic receptor plays a role in various physiological processes.
  • Developing selective agonists for the beta3 adrenergic receptor is of therapeutic interest.

Purpose of the Study:

  • To synthesize and evaluate novel N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides.
  • To identify potent and selective human beta3 adrenergic receptor agonists.

Main Methods:

  • Structure-Activity Relationship (SAR) studies were conducted.
  • Synthesis of a series of arylglycinamide derivatives.
  • In vitro evaluation of receptor agonist activity.

Main Results:

  • Identified BMS-201620 as a potent full agonist of the human beta3 adrenergic receptor.

Related Experiment Videos

  • BMS-201620 exhibited a high affinity (Ki = 93 nM) and efficacy (93% activation).
  • The compound demonstrated a favorable safety profile in preliminary assessments.

    • Conclusions:

    • BMS-201620 represents a promising drug candidate for targeting the beta3 adrenergic receptor.
    • The favorable safety profile supports its advancement into clinical evaluation.
    • Further clinical studies are warranted to explore the therapeutic potential of BMS-201620.